Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

99.18 -0.68 (-0.68%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
95 96 Next >
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
From Merck & Co., Inc.
Via Business Wire
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
EQNX::TICKER_START (OTCPK:MUSLF),(CSE:MUSL),(NYSE:MRK),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
Market Analysis: Merck &amp; Co And Competitors In Pharmaceuticals Industry
Via Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Exposures US Equities
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
From FN Media Group LLC
Via GlobeNewswire
Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Jim Cramer Advises Investors To Brace For Economic Slowdown, Shares Tips To Maintain Balanced Portfolio: 'I'm Not Telling You To Relax'
Jim Cramer, the host of CNBC's "Mad Money," has warned investors about the current state of the economy and suggested strategies to navigate the challenging period. 
Via Benzinga
Topics Economy
Exposures Economy
A Look At Pharma ETFs Post Q1 Earnings
Pharma ETFs have delivered mixed performances over the past month. 
Via Talk Markets
Topics ETFs
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Biotech Stocks to Double Your Money in the Next 24 Months
The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates. 
Via InvestorPlace
In a market where value is scarce, NYSE:MRK offers a refreshing opportunity with its solid fundamentals.
MERCK & CO. INC. (NYSE:MRK) stands out as a stock that provides good value for the fundamentals it showcases. 
Via Chartmill
Serum Institute of India Inks Large-Scale Supply Deal For BCG Use In ImmunityBio's Bladder Cancer Combo Therapy
Unlocking global access to Bacillus Calmette-Guerin (BCG) for cancer therapy. ImmunityBio partners with Serum Institute to expand BCG supply. FDA-approved Anktiva plus BCG for bladder cancer. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouraging data from its Phase III gastric cancer treatment trial after... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
From Merck & Co., Inc.
Via Business Wire
Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates
The first-quarter 2024 earnings season picked up pace this week, with Merck, Sanofi, Novartis, and AstraZeneca announcing their first-quarter results. Three of the four companies beat estimates for... 
Via Talk Markets
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser. 
Via Investor's Business Daily
Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points
Via Benzinga
Topics Stocks
Exposures US Equities
Merck (MRK) Q1 2024 Earnings Call Transcript
MRK earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
Wall Street suffers a double blow in Thursday’s session, as softer-than-expected revenue forecasts from Meta Platforms Inc. (NASDAQ:META) are being compounded by weaker-than-expected economic growth... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
Merck reported Q1 sales of $15.8 billion, beating estimates, with cancer drug Keytruda driving growth. Company raised full-year revenue and EPS forecasts. 
Via Benzinga
S&P 500 Down Over 1%; Merck Increases 2024 Outlook
Via Benzinga
Topics Stocks
Exposures US Equities
MRK Stock Earnings: Merck & Co Beats EPS, Beats Revenue for Q1 2024
MRK stock results show that Merck & Co beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Meta Falls 15% On Great Earnings, Tesla Rises 12% On Ugly Earnings – Here Is The Real Reason
To gain an edge, this is what you need to know today. 
Via Benzinga
Merck Rides Keytruda To Another Beat-And-Raise, But Diabetes Headwinds Persist
Merck's bread-and-butter cancer drug grew by double digits again in the first quarter. 
Via Investor's Business Daily
Merck Announces First-Quarter 2024 Financial Results
From Merck & Co., Inc.
Via Business Wire
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NASDAQ:META) 
Via Benzinga
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients without PD-L1 expression. Final data expected in H1 CY2024. 
Via Benzinga
Investor Alert: Prepare for the Market Crash With These 3 Stocks
These are the low-beta and attractively valued stocks to buy for a market crash as they represent companies with strong fundamentals. 
Via InvestorPlace
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
95 96 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.